Compare SBET & ODTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBET | ODTX |
|---|---|---|
| Founded | 1995 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2025 | 2025 |
| Metric | SBET | ODTX |
|---|---|---|
| Price | $7.47 | $18.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $16.63 | ★ $35.33 |
| AVG Volume (30 Days) | ★ 6.6M | 246.3K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,055,000.00 | N/A |
| Revenue This Year | $67.70 | N/A |
| Revenue Next Year | $57.94 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 666.04 | N/A |
| 52 Week Low | $4.46 | $15.10 |
| 52 Week High | $14.85 | $29.05 |
| Indicator | SBET | ODTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 41.44 |
| Support Level | $6.05 | $15.10 |
| Resistance Level | $8.20 | $19.60 |
| Average True Range (ATR) | 0.43 | 1.35 |
| MACD | -0.26 | -0.16 |
| Stochastic Oscillator | 1.86 | 23.11 |
Sharplink Inc is one of those publicly traded companies to adopt ETH as its primary treasury reserve asset. This move reflects the Company's commitment to align corporate treasury with the future of programmable finance, digital capital markets, and decentralized infrastructure. The Company also operates an online affiliate marketing company that delivers different fan activation solutions to its sportsbook and online casino gaming partners. The company operates in two reportable segments: ETH Treasury Management and Affiliate Marketing. The majority of its revenue is generated from the ETH Treasury Management. Geographically, the company operates in the United States and the rest of the world.
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.